Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 11, 2009, Pages 4809-4815

  Foweraker, Juliet E ^a   Laughton, Christian R ^a   Brown, Derek F ^b   Bilton, Diana ^a,c  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFTAZIDIME; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TREATMENT RESPONSE;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ELECTROPHORESIS, GEL, PULSED-FIELD; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM;

EID: 70350279548     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00269-09     Document Type: Article

References (41)

1. Aaron, S. D., D. Kottachchi, W. J. Ferris, K. L. Vandemheen, M. L. St. Denis, A. Plouffe, S. P. Doucette, R. Saginur, F. T. Chan, and K. Ramotar. 2004. Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis. Eur. Respir. J. 24:631-637.
2. Aaron, S. D., K. L. Vandemheen, W. Ferris, D. Fergusson, E. Tullis, D. Haase, Y. Berthiaume, N. Brown, P. Wilcox, V. Yozghatlian, P. Bye, S. Bell, F. Chan, B. Rose, A. Jeanneret, A. Stephenson, M. Noseworthy, A. Freitag, N. Paterson, S. Doucette, C. Harbour, M. Ruel, and N. MacDonald. 2005. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366:463-471.
3. Andrews, J. M. 2001. Determination of minimum inhibitory concentrations. J. Antimicrob. Chemother. 48(Suppl. 1):5-16.
4. Anonymous. 2002. Antibiotic treatment for cystic fibrosis. Report of the United Kingdom Cystic Fibrosis Trust's Antibiotic Group, 2nd ed. Cystic Fibrosis Trust, Bromley, United Kingdom.
5. Balke, B., M. Hogardt, S. Schmoldt, L. Hoy, H. Weissbrodt, and S. Haussler. 2006. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 25:25-30.
6. Bosso, J. A., B. A. Saxon, and J. M. Matsen. 1990. In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis. Antimicrob. Agents Chemother. 34:487-488.
7. Cappelletty, D. M., and M. J. Rybak. 1996. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 40:677-683.
8. Ceri, H., M. E. Olson, C. Stremick, R. R. Read, D. Morck, and A. Buret. 1999. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 37:1771-1776.
9. Chandrasekar, P. H., L. R. Crane, and E. J. Bailey. 1987. Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in nonneutropenic patients. J. Antimicrob. Chemother. 19:321-329.
10. Doring, G., S. P. Conway, H. G. Heijerman, M. E. Hodson, N. Hoiby, A. Smyth, and D. J. Touw. 2000. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 16:749-767.
11. Drago, L., E. De Vecchi, L. Nicola, L. Tocalli, and M. R. Gismondo. 2005. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with betalactams and amikacin. J. Antimicrob. Chemother. 56:353-359.
12. Duan, K., C. Dammel, J. Stein, H. Rabin, and M. G. Surette. 2003. Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. Mol. Microbiol. 50:1477-1491.
13. Fonseca, A. P., C. Extremina, A. F. Fonseca, and J. C. Sousa. 2004. Effect of subinhibitory concentration of piperacillin/tazobactam on Pseudomonas aeruginosa. J. Med. Microbiol. 53:903-910.
14. Fothergill, J. L., S. Panagea, C. A. Hart, M. J. Walshaw, T. L. Pitt, and C. Winstanley. 2007. Widespread pyocyanin over-production among isolates of a cystic fibrosis epidemic strain. BMC Microbiol. 7:45.
15. Foweraker, J. E., C. R. Laughton, D. F. Brown, and D. Bilton. 2005. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J. Antimicrob. Chemother. 55:921-927.
16. Fuchs, H. J., D. S. Borowitz, D. H. Christiansen, E. M. Morris, M. L. Nash, B. W. Ramsey, B. J. Rosenstein, A. L. Smith, M. E. Wohl, et al. 1994. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N. Engl. J. Med. 331:637-642.
17. Giwercman, B., P. A. Lambert, V. T. Rosdahl, G. H. Shand, and N. Hoiby. 1990. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed betalactamase producing strains. J. Antimicrob. Chemother. 26:247-259.
18. Giwercman, B., C. Meyer, P. A. Lambert, C. Reinert, and N. Hoiby. 1992. High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment. Antimicrob. Agents Chemother. 36:71-76.
19. Govan, J. R., J. A. Fyfe, and N. R. Baker. 1983. Heterogeneity and reduction in pulmonary clearance of mucoid Pseudomonas aeruginosa. Rev. Infect. Dis. 5(Suppl. 5):S874-S849.
20. Gunderson, B. W., K. H. Ibrahim, L. B. Hovde, T. L. Fromm, M. D. Reed, and J. C. Rotschafer. 2003. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 47:905-909.
21. Hancock, R. E., V. J. Raffle, and T. I. Nicas. 1981. Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 19:777-785.
22. Ichimiya, T., T. Yamasaki, and M. Nasu. 1994. In-vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation. J. Antimicrob. Chemother. 34:331-341.
23. Jain, M., D. Ramirez, R. Seshadri, J. F. Cullina, C. A. Powers, G. S. Schulert, M. Bar-Meir, C. L. Sullivan, S. A. McColley, and A. R. Hauser. 2004. Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis. J. Clin. Microbiol. 42:5229-5237.
24. Kaufman, M. E. 1998. Pulsed field gel electrophoresis. Methods Mol. Med. 15:33-50.
25. Lang, B. J., S. D. Aaron, W. Ferris, P. C. Hebert, and N. E. MacDonald. 2000. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med. 162:2241-2245.
26. Lechtzin, N., M. John, R. Irizarry, C. Merlo, G. B. Diette, and M. P. Boyle. 2006. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 73:27-33. (Pubitemid 43296235)
27. Livermore, D. M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634-640.
28. McLaughlin, F. J., W. J. Matthews, Jr., D. J. Strieder, B. Sullivan, A. Taneja, P. Murphy, and D. A. Goldmann. 1983. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J. Infect. Dis. 147:559-567.
29. Miller, M. H., S. A. Feinstein, and R. T. Chow. 1987. Early effects of beta-lactams on aminoglycoside uptake, bactericidal rates, and turbidimetrically measured growth inhibition in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 31:108-110.
30. Moskowitz, S. M., J. M. Foster, J. Emerson, and J. L. Burns. 2004. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J. Clin. Microbiol. 42:1915-1922.
31. Pillai, S., R. Moellering, and G. Eliopoulos. 2005. Antimicrobial combinations, p. 365-440. In V. Lorian (ed.), Antibiotics in laboratory medicine, 5th ed. Lippincott Williams & Wilkins, Baltimore, MD.
32. Pitt, T. L., M. Sparrow, M. Warner, and M. Stefanidou. 2003. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 58:794-796. (Pubitemid 37094057)
33. Rogers, G. B., M. P. Carroll, D. J. Serisier, P. M. Hockey, G. Jones, V. Kehagia, G. J. Connett, and K. D. Bruce. 2006. Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. J. Clin. Microbiol. 44:2601-2604.
34. Saiman, L. 2007. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'. Paediatr. Respir. Rev. 8:249-255.
35. Saiman, L., F. Mehar, W. W. Niu, H. C. Neu, K. J. Shaw, G. Miller, and A. Prince. 1996. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin. Infect. Dis. 23:532-537.
36. Sanchez, P., J. F. Linares, B. Ruiz-Diez, E. Campanario, A. Navas, F. Baquero, and J. L. Martinez. 2002. Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. J. Antimicrob. Chemother. 50:657-664.
37. Smith, A. L., S. B. Fiel, N. Mayer-Hamblett, B. Ramsey, and J. L. Burns. 2003. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 123:1495-1502.
38. Tunney, M. M., T. R. Field, T. F. Moriarty, S. Patrick, G. Doering, M. S. Muhlebach, M. C. Wolfgang, R. Boucher, D. F. Gilpin, A. McDowell, and J. S. Elborn. 2008. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 177:995-1001.
39. Visalli, M. A., M. R. Jacobs, and P. C. Appelbaum. 1998. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology. Antimicrob. Agents Chemother. 42:953-955.
40. Weiss, K., and J. R. Lapointe. 1995. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:2411-2414.
41. Wolter, J. M., S. D. Bowler, and J. G. McCormack. 1999. Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis? Aust. N. Z. J. Med. 29:15-21.